Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced findings of a new analysis of long-term follow-up data from the Phase III JAVELIN Bladder 100 trial.
Statistically significant 133% faster time to COVID-19 clinical symptoms recovery versus standard of care (SOC)/best supportive care. Statistically significant.
There is particular interest in monoclonal antibody agents to determine whether their immune suppressive effects can reduce the immediate and long-term impact of COVID-19.